Recurrent exacerbations affect FEV1 decline in adult patients with cystic fibrosis

被引:49
作者
Amadori, Anna [1 ]
Antonelli, Andrea [1 ]
Balteri, Ilaria [1 ]
Schreiber, Anja [1 ]
Bugiani, Massimiliano [2 ]
De Rose, Virginia [1 ]
机构
[1] Univ Turin, S Luigi Hosp, Dept Clin & Biol Sci, Resp Dis Div, I-10043 Turin, Italy
[2] Local Hlth Agcy 4, Unit Resp Dis, Turin, Italy
关键词
Cystic fibrosis in adults; Exacerbations; FEV1; decline; PULMONARY-FUNCTION; LUNG-FUNCTION; DIABETES-MELLITUS; COMPUTED-TOMOGRAPHY; NUTRITIONAL-STATUS; ASPERGILLOSIS; SURVIVAL; CHILDREN; THERAPY;
D O I
10.1016/j.rmed.2008.09.024
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Obstructive lung disease is the major cause of morbidity and mortality in cystic fibrosis (CF). To identify risk factors contributing to FEV1 decline in CF patients, we carried out a retrospective analysis of clinical and pulmonary function data in a population of CF patients followed up for 5 years and studied the correlation between clinical data and FEV1 decline. Fifty-one adult CF patients were studied. The FEV1 decline was related to the following clinical characteristics: CFTR genotype, age, gender, weight, height, age at diagnosis, baseline FEV1, pancreatic function, presence of airway infection, pancreatic insufficiency and diabetes, number of exacerbations/year and intravenous (i.v.) antibiotic courses/year. Both the number of exacerbations/year and the number of i.v. antibiotic courses/year were strongly related to the FEV1 decline. Patients with airway infection or with diabetes had significantly lower FEV1 values during the study as compared with non-infected patients or patients without diabetes; however, both the presence of airway infection or diabetes did not affect the FEV1 decline. These results suggest that the aggressive treatment of disease exacerbations is crucial for delaying lung function decline in CF. (C) 2008 Elsevier Ltd. All rights reserved.
引用
收藏
页码:407 / 413
页数:7
相关论文
共 39 条
  • [2] [Anonymous], 1997, CLIN PRACTICE GUIDEL
  • [3] How useful is fecal pancreatic elastase 1 as a marker of exocrine pancreatic disease?
    Beharry, S
    Ellis, L
    Corey, M
    Marcon, M
    Durie, P
    [J]. JOURNAL OF PEDIATRICS, 2002, 141 (01) : 84 - 90
  • [4] Longitudinal analysis of pulmonary function decline in patients with cystic fibrosis
    Corey, M
    Edwards, L
    Levison, H
    Knowles, M
    [J]. JOURNAL OF PEDIATRICS, 1997, 131 (06) : 809 - 814
  • [5] Cystic fibrosis
    Davis, PB
    Drumm, M
    Konstan, MW
    [J]. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 1996, 154 (05) : 1229 - 1256
  • [6] Identifying treatments that halt progression of pulmonary disease in cystic fibrosis
    Davis, PB
    Byard, PJ
    Konstan, MW
    [J]. PEDIATRIC RESEARCH, 1997, 41 (02) : 161 - 165
  • [7] Progressive damage on high resolution computed tomography despite stable lung function in cystic fibrosis
    de Jong, PA
    Nakano, Y
    Lequin, MH
    Mayo, JR
    Woods, R
    Paré, PD
    Tiddens, HAWM
    [J]. EUROPEAN RESPIRATORY JOURNAL, 2004, 23 (01) : 93 - 97
  • [8] Fcγ receptor IIA genotype and susceptibility to P-aeruginosa infection in patients with cystic fibrosis
    De Rose, V
    Arduino, C
    Cappello, N
    Piana, R
    Salmin, P
    Bardessono, M
    Goia, M
    Padoan, R
    Bignamini, E
    Costantini, D
    Pizzamiglio, G
    Bennato, V
    Colombo, C
    Giunta, A
    Piazza, A
    [J]. EUROPEAN JOURNAL OF HUMAN GENETICS, 2005, 13 (01) : 96 - 101
  • [9] Circulating adhesion molecules in cystic fibrosis
    De Rose, V
    Oliva, A
    Messore, B
    Grosso, B
    Mollar, C
    Pozzi, E
    [J]. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 1998, 157 (04) : 1234 - 1239
  • [10] Mechanisms and markers of airway inflammation in cystic fibrosis
    De Rse, V
    [J]. EUROPEAN RESPIRATORY JOURNAL, 2002, 19 (02) : 333 - 340